Full-Time

Associate Director Crystallization

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Lab & Research
Physical Sciences
Requirements
  • PhD in Chemical engineering or Solid State Chemistry with a minimum of 8 years experience in industry or academia or a master’s degree with a minimum of 12 years of experience.
  • Proven track record developing and leading other to develop crystallization processes.
  • An ability to work as part of a team, engaging other scientists with complementary skill sets in the field of pharmaceutical development.
  • A change agent mentality, proposing novel approach to challenging scientific questions and exploring new modeling approaches.
  • Ability to design and deliver lab experimental plans for crystallization process development including use of typical process and analytical experiment.
  • Familiar with PAT and common off-line analytical technics such as HPLC, GC and NMR.
Responsibilities
  • Lead a team that works with internal partners in Drug Product development, Biopharmaceutics and Analytical to select the API physical form for new NCEs. This includes assessment of the manufacturability (API solid form space complexity, physical properties, scalability, stability)
  • Develop and mentor others to develop processes to consistently produce API with the required quality attributes using both batch and continuous platforms. Expectations include; Team Interactions – Facilitate close interactions with project team members such as Chemists, Analysts, Formulators and Engineers/Modelers to develop API processes that are closely coordinated with API route selection and Drug Product development.
  • Digital Development – Lead the transformation of development from traditional data driven statistical approaches to more efficient and effective Digital Development.
  • Domain knowledge - Use a strong background in Crystallization Engineering and/or Solid-State Chemistry to understand and apply strategies to control API physiochemical properties such as particle size distribution, impurities concentration and crystal form.
  • Experimentation – Apply strong lab skills to deliver well designed efficient experimental plans required for process development across a wide range of crystallization, isolation and size reduction process equipment.
  • Analytical – Perform physiochemical analysis to understand process and characterize products this includes but is not limited to XRD, DSC, PSD, SEM, optical microscopy, LC, GC, KF.
  • The candidate will be expected to dedicate part of their time to work on continuous improvement with internal resource or through academic collaboration. Some potential areas for improvement include; Development of models to understand and describe the rejection of impurities in intermediate and API crystallizations.
  • Develop crystallization models (Digital Twins) for batch and continuous process and use Global System Analysis tools (e.g. gPROMS) to identify CPPs, Design Space and Control Strategies.
  • Identify and test Particle Engineering approaches to improve API physical properties such as supersaturation control, seed conditioning and agglomeration.
  • Author publications, patents and present in technical conferences.
  • Lead Tech Transfer of crystallization to the Pilot Plant and Manufacturing. This includes support for technical and HSE risk assessments, review of Master Batch Records and campaign coverage for key batches.
  • Provide concise technical presentations to communicate work to project teams, cross functional teams and management. Document all work on projects and continuous improvements in eLNB experiments and summarize in Technical Reports.
  • Establish/extend external network by providing leadership on academic, industrial, or government sponsored collaborations. Steer collaboration projects to address gaps in scientific knowledge.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and a global presence. The company's goal is to enhance health outcomes and improve the quality of life for individuals worldwide.

Company Stage

Grant

Total Funding

$2B

Headquarters

Paris, France

Founded

N/A

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's strong financial performance, as evidenced by its raised 2024 outlook, indicates robust growth and stability.
  • The company's strategic investments in innovative biotech firms, such as Ventyx Biosciences, enhance its pipeline and potential for breakthrough therapies.
  • Sanofi's Dupixent receiving a positive recommendation for expanded use in children demonstrates its leadership in addressing unmet medical needs.

What critics are saying

  • The highly competitive pharmaceutical market requires Sanofi to continuously innovate to maintain its market position.
  • Regulatory challenges in different regions could delay product approvals and impact revenue streams.

What makes Sanofi unique

  • Sanofi's extensive R&D efforts and strategic partnerships, such as with Orano Med for radioligand therapies, set it apart in the competitive pharmaceutical landscape.
  • The company's global reach and focus on patient-centric solutions allow it to effectively navigate diverse regulatory environments and deliver innovative treatments worldwide.
  • Sanofi's investment in sustainable initiatives, like SureChill's 'Cooling as a Service' model, highlights its commitment to addressing healthcare challenges in emerging markets.

Help us improve and share your feedback! Did you find this helpful?